Samaritan fusion inhibitor progress
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Samaritan expects to begin a Phase II/III monotherapy trial of its HIV fusion/entry inhibitor SP-01A in the second quarter, the firm says March 1. The trial will look at HIV patients experiencing resistance to antiretroviral therapy. Samaritan is touting SP-01A's oral capsule formulation as an advantage over the only marketed fusion inhibitor, Roche/Trimeris' subcutaneous Fuzeon (enfuvirtide). Other firms with fusion inhibitors in development include Progenics and Biogen Idec...